The online version of this article (doi:10.1186/1129-2377-15-43) contains supplementary material, which is available to authorized users.
Shuang Li, Yuan Chen, Hai-Feng Zhang contributed equally to this work.
The authors declare that they have no competing interest.
YJL study concept and design. SL acquisition of data. HFZ carried out the treatment and studies, drafted the manuscript. YC participated in the sequence alignment, analysis and interpretation. YQM, CHH, CJW revise the manuscript. NCX, YKZ, YC study supervision. All authors read and approved the final manuscript.
We investigated the long-term effects and safety of botulinum toxin-A (BTX-A) for treating trigeminal neuralgia (TN). We also studied long-term maintenance of this therapeutic effect.
A visual analog scale (VAS) score, pain attack frequency per day, patient’s overall response to treatment and side effects during 14-month follow-up were evaluated in 88 patients with TN receiving BTX-A. The primary endpoints were pain severity (assessed by VAS) and pain attack frequency per day. The secondary endpoint was the patient’s overall response to treatment, assessed using the Patient Global Impression of Change. The influence of different doses (≤50, 50–100 and ≥100 U) on the therapeutic effect was evaluated.
Treatment was deemed “effective” within 1 month in 81 patients and at 2 months in 88 patients (100%). The shortest period of effective treatment was 3 months, and complete control of pain was observed in a maximum of 46 patients. The therapeutic effect decreased gradually after 3 months, and the prevalence of effective treatment at 14 months was 38.6%, with complete control of pain seen in 22 patients (25%). There was no significant difference in the prevalence of effective treatment between different dose groups at identical time points (p > 0.05). Three patients showed swelling at injection sites and 10 patients showed facial asymmetry, both of which disappeared spontaneously without special treatment.
Local subcutaneous injection of BTX-A for TN treatment has considerable therapeutic effects lasting several months and is safe for this indication. At least one-quarter of patients maintained complete analgesia. The maintenance period of the therapeutic effect may be related to the reduction in the VAS score after the first injection of BTX-A.
Lian YJ, Wei HL, Zhang BA, Liu HB, Xu YM, Fang SY, Li ZF, Fang GY, Lu H, Jia YJ, Zhao XY, Wei JK, Zhang L, Song B: Treatment of 795 facial spasm and local dystonia with Botulinum toxin A. J Zhengzhou Univ (Med Sci) 2009, 44(2):440–442.
Shen JH, Lian YJ, Zheng YK, Xie YY, Wei HL: Treatment of primary trigeminal neuralgia with botulinum toxin type A. China J Rehabil Med 2011, 26(5):483–484.
Zhu TG, Zhang QL, Luo WF, Mao CJ, Hu WD, Liu CF: Clinical treatment of refractory trigeminal neuralgia with botulinum toxin type A. China Clinical Neuroscience 2011, 19(1):32–35.
Gustavo F, Jose DA, Villanueva P, Asensio-Samper JM: Subcutaneous and perineural Botulinum Toxin Type A For Neuropathic Pain. Clin J Pain 2013. [Epub ahead of print]
Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D: Subcutaneous injection of botulium toxin A is beneficial in postherpetic neuralgia. Pain Med 2011, 11: 1827–1833. CrossRef
Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ: Botulinum toxin for diabetic neuropathic pain:a randomized double-blind crossover trial. Neurology 2009, 72: 1456–1478. CrossRef
Wu CJ, Lian YJ: Botulium toxin type A for trigeminal neuralgia-we have the prima facie evidence. Cephalagia 2012, 32(15):1156–1157. CrossRef
- Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-up
- Springer Milan
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II